CJC-1295 + Ipamorelin Stack: The Complete Growth Hormone Protocol (2026)

Key Takeaways

• The CJC-1295 + Ipamorelin stack is a growth hormone secretagogue protocol designed to enhance growth hormone release.
• It combines two peptides: CJC-1295, a GHRH analog, and Ipamorelin, a GHRP, both administered via subcutaneous injection.
• This stack is used for anti-aging, muscle recovery, and improving body composition.
• Typical protocol duration ranges from 8 to 12 weeks.
• Both CJC-1295 and Ipamorelin are classified as FDA Category 2, meaning they are prohibited for compounding as of 2024.

What Is the GH Secretagogue Stack (CJC-1295 + Ipamorelin)?

The GH Secretagogue Stack, comprising CJC-1295 and Ipamorelin, is a popular peptide protocol designed to stimulate the body's growth hormone (GH) production. This combination is favored for its ability to mimic the body's natural GH release patterns, offering benefits such as anti-aging effects, muscle recovery, and improved body composition.

Regulatory Status

Both CJC-1295 and Ipamorelin are classified as FDA Category 2, making them prohibited for compounding in the United States as of 2024. They are primarily available for research purposes and are not approved for general medical use.

How the GH Secretagogue Stack (CJC-1295 + Ipamorelin) Works

Individual Mechanisms of Action

• CJC-1295: This peptide is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to release GH. It has a prolonged effect due to its ability to bind to serum albumin, extending its half-life (PMID 16352683).
• Ipamorelin: A growth hormone-releasing peptide (GHRP), Ipamorelin selectively stimulates the ghrelin receptor, promoting GH release with minimal impact on cortisol and prolactin levels (PMID 10373343).

Synergistic Effects

The combination of CJC-1295 and Ipamorelin leverages their complementary mechanisms to enhance GH release more effectively than either peptide alone. CJC-1295 provides a sustained release of GH, while Ipamorelin induces pulsatile releases, closely mimicking the body's natural GH secretion patterns (PMID 41490200).

GH Secretagogue Stack (CJC-1295 + Ipamorelin) Dosing Protocol

This protocol typically involves injecting both peptides subcutaneously before bedtime, five days on and two days off, to optimize GH release while minimizing receptor desensitization.

Administration Guide

• Mixing: CJC-1295 and Ipamorelin can be mixed in the same syringe for convenience.
• Injection Timing: Administer injections at least 30 minutes before meals to maximize GH release.
• Reconstitution: Use bacteriostatic water to reconstitute peptides. Store reconstituted peptides in the refrigerator.
• Equipment: Use insulin syringes (29-31 gauge) for subcutaneous injections.

Who Is This Protocol For?

Athletes Recovering from Injury

Athletes often use this stack to accelerate recovery from injuries due to its ability to enhance tissue repair and reduce recovery time.

Post-Surgical Recovery

Patients recovering from surgery may benefit from the stack's potential to promote healing and reduce inflammation.

Anti-Aging / Longevity Goals

The stack is popular among individuals seeking anti-aging benefits, as increased GH levels can improve skin elasticity and overall vitality.

Specific Conditions

Conditions such as hypogonadism or metabolic syndrome may see symptomatic improvement through the stack's effects on body composition and energy levels (PMID 32257855).

Expected Results and Timeline

• Week 1-2: Users commonly report increased energy levels and improved sleep quality.
• Week 3-4: Enhanced muscle recovery and slight improvements in body composition may become noticeable.
• Week 5-8: Full effects on muscle mass, recovery, and skin elasticity typically manifest.
• Post-Cycle: Gradual tapering of effects; ongoing benefits may persist with proper lifestyle adjustments.

Potential Side Effects and Risks

• Common Side Effects: Injection site reactions, water retention, and mild headaches.
• Contraindications: Not recommended for individuals with active cancer or diabetic retinopathy.
• Drug Interactions: Caution with concurrent use of other GH-modulating therapies.
• Monitoring: Regular bloodwork to monitor GH and IGF-1 levels is advised.

Legal and Regulatory Status

• CJC-1295: Research-only, FDA Category 2 (prohibited for compounding).
• Ipamorelin: Research-only, FDA Category 2 (prohibited for compounding).

Clinics in the U.S. cannot legally prescribe this protocol for general therapeutic use. It remains available for research purposes only.

Alternative Protocols

• Tesamorelin + GHRP-6: Targets similar goals with legally available peptides.
• Sermorelin + GHRP-2: An alternative stack for GH release with fewer regulatory restrictions.
• BPC-157 + TB-500: Focuses on tissue repair and recovery.

What the Evidence Does Not Show

While individual peptides like CJC-1295 and Ipamorelin have shown promise in clinical studies, the specific combination lacks extensive human trials. Most data are extrapolated from individual peptide studies, and long-term effects remain uncertain.

FAQ

How long should I run this protocol?

The typical cycle lasts 8-12 weeks, followed by a break to prevent receptor desensitization.

Can I modify the doses?

Dosing should be tailored by a healthcare professional based on individual response and goals.

Is this protocol legal?

No, both peptides are FDA Category 2 and prohibited for compounding in the U.S.

Do I need a prescription?

Yes, a prescription is required for legal use in research settings.

Can women use this protocol?

Yes, women can use this protocol, but dosing and monitoring should be managed by a healthcare provider.

What bloodwork should I get?

Monitor GH and IGF-1 levels to assess the protocol's effects.

Where can I find a clinic that offers this?

Visit our clinic finder to locate a peptide therapy clinic near you.

---

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.